ArticleCancer communications (London, England)2025
Phase II study evaluating the safety and efficacy of neratinib and trastuzumab biosimilar in patients with HER2 mutated advanced solid tumors: KCSG AL20-17/KM23 trial.
Kyoungmin Lee et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.